CareDx, Inc.

CareDx, Inc.

CDNANYSE / NASDAQHealthcareSmall cap

$70.00-$1.92 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$1.2B
P/E
-55.9x
EV / EBITDA
-248.1x
Revenue
$379.8M
Net margin
-5.6%
ROCE
-7.8%

+344.2% over the last year

CareDx, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+1.2%
3M
+49.0%
6M
+231.0%
1Y
+344.2%
5Y
+62.8%

52-week range

Day change -$1.92 (-2.7%) from $72 to $70 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CDNA, bought on each weekday since 2021.

News & filings

What CareDx filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 21.4 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 84.0% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.

Read moreShow less

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Sector
Healthcare
Shares outstanding
50.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.2B
P/E
-55.9x
P/B
3.9x
EV / EBITDA
-248.1x
EV / Sales
3.0x
P/S
3.1x
52-week high
$88.47
52-week low
$15.76

Profitability

Operating margin
-6.6%
Net margin
-5.6%
EBITDA margin
-1.2%
ROE
-7.0%
ROCE
-7.8%
ROIC
-7.5%
ROA
-5.2%
Asset turnover
0.92

Growth

Revenue
$379.8M
Revenue growth, 1Y
13.8%
Revenue CAGR, 3Y
5.7%
Net profit growth, 1Y
-140.6%
Free cash flow
$35.4M

Solvency

Current ratio
2.86
Debt / Equity
0.09
Debt / Assets
0.06
CFO / Net profit
-1.97
Cash / Market cap
5.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$379.8M
Cost of revenue$123.2M
Gross profit$256.6M
Operating expenses$281.6M
Research and development$71.4M
Selling, general and administrative$210.2M
Operating income-$25.1M
Interest and other$4.0M
Pretax income-$21.1M
Tax and other$270.0k
Net income-$21.4M

Revenue and net profit

Revenue grew 13.8% in FY2025; net profit is the dashed line.

CareDx, Inc. revenue and net profit by fiscal year
CareDx, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$321.8M-$76.6M
FY2023$280.3M-$190.3M
FY2024$333.8M$52.5M
FY2025$379.8M-$21.4M

Cash flows

FY2025: $42.0M from operations, $35.4M free after investment (dashed).

CareDx, Inc. operating and free cash flow by fiscal year
CareDx, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$25.2M-$49.6M
FY2023-$18.4M-$27.6M
FY2024$38.0M$31.6M
FY2025$42.0M$35.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$379.8M+13.8%1Y
EBITDA
-$4.7M
Net profit
-$21.4M-140.6%1Y
Cash from operations
$42.0M+10.5%1Y
Free cash flow
$35.4M+12.3%1Y
Revenue CAGR, 3Y
5.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$379.8M-$4.7M-$21.4M$35.4M-7.0%+13.8%-140.6%

Monthly returns

Month-by-month returns of CDNA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$413.2M
Liabilities$110.1M
Equity$303.1M
Paid-in capital$1.0B
Retained earnings-$735.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CDNA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. CareDx, Inc. (this company)3.0x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
CareDx, Inc.CDNAthis company$1.2B-55.9x3.9x-7.0%-248.1x
Alphatec Holdings, Inc.ATEC$1.2B—98.1x-1154.3%—
Inspire Medical Systems, Inc.INSP$1.2B8.4x1.6x18.6%14.3x
IRADIMED CORPORATIONIRMD$1.2B53.2x12.6x23.8%41.9x
Kestra Medical Technologies, Ltd.KMTS$1.2B-10.5x5.8x-55.4%-10.2x
AMN Healthcare Services, Inc.AMN$1.2B—1.8x-14.9%19.3x
Schrödinger, Inc.SDGR$1.2B-11.5x3.3x-28.4%-6.6x
Wave Life Sciences Ltd.WVE$1.2B—2.3x-39.4%—
Avanos Medical, Inc.AVNS$1.2B—1.5x-9.4%—
Peer median—-1.1x2.8x-21.6%14.3x

Year-to-date ROI

CDNA since 1 January, against earlier years.

Historical volatility

CDNA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

CareDx, Inc. operating margin by fiscal year
CareDx, Inc. operating margin by fiscal year
DateOperating margin
FY2022-24.0%
FY2023-38.2%
FY2024-16.6%
FY2025-6.6%
LineFY2025
Cost of revenueCost Of Revenue$123.2M
Gross profitGross Profit$256.6M
Operating expensesOperating Expense$281.6M
Research and developmentResearch And Development$71.4M
Total expensesTotal Expenses$404.9M
Pretax incomePretax Income-$21.1M

Learn while you research

Academy chapters picked for CareDx, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →